Trial Profile
A randomized, single-blind, placebo-controlled, 4-way crossover phase I pharmacokinetic (PK) study of ORMD-0901
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Oramed Pharmaceuticals
- 27 Feb 2020 According to an Oramed Pharmaceuticals media release, the company announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $4.00 per share and the company intends to use the net proceeds of the offering for this trial.
- 18 Jun 2019 Status changed from recruiting to completed, according to an Oramed Pharmaceuticals media release.
- 15 Jan 2019 Status changed from planning to recruiting, according to an Oramed Pharmaceuticals media release.